SCHEDULE: FMR LLC Boosts Moderna Stake to 10.6%

FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 10.6% of Moderna Inc.'s common stock as of January 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson reported beneficial ownership of 41,301,468.88 shares of Moderna Inc. common stock.
• This represents 10.6% of the total outstanding common stock of Moderna Inc.
• The filing is an Amendment No. 1 to a Schedule 13G, updating previous beneficial ownership information.
• FMR LLC holds sole voting power over 41,192,005.42 shares and sole dispositive power over 41,301,468.88 shares.
• Abigail P. Johnson holds sole dispositive power over 41,301,468.88 shares.
• FMR LLC is identified as a parent holding company, and Abigail P. Johnson is an individual, also serving as Director, Chairman, and CEO of FMR LLC.
• Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC (which beneficially owns 5% or more), are listed as entities holding shares.
• The Johnson family, including Abigail P. Johnson, are predominant owners of FMR LLC's voting shares, forming a controlling group.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a major institutional investor maintaining a significant stake suggests continued confidence in Moderna Inc. However, it is a routine regulatory filing and does not provide new operational or financial insights.

Positives

• A significant institutional investor, FMR LLC, maintains a substantial 10.6% stake in Moderna Inc., indicating continued confidence in the company.
• The beneficial ownership is held by a well-established financial services firm, suggesting a thorough investment analysis process.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Moderna Inc.'s future performance or outlook.

Industry Context

StockSavvy.ai notes that large institutional ownership, such as the 10.6% stake held by FMR LLC, is common for established publicly traded companies like Moderna Inc. Such significant holdings by major asset managers often signal long-term investment strategies and can provide a degree of stability to the stock by reducing volatility from smaller, more speculative trades. This level of ownership by a prominent investment firm like Fidelity (FMR LLC's parent) is generally viewed positively within the investment community, reflecting confidence in the company's market position and future prospects within the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• FMR LLC's 10.6% stake in Moderna Inc. is a substantial position, comparable to other major institutional investors holding significant percentages in leading biotechnology and pharmaceutical companies. For instance, Vanguard Group often holds similar or larger stakes (e.g., 8-12%) in companies like Pfizer (PFE) or Johnson & Johnson (JNJ) through its various funds.
• BlackRock, another major asset manager, also frequently reports beneficial ownership exceeding 5% in numerous large-cap pharmaceutical firms, reflecting a common strategy of diversified, long-term holdings in established industry players.
• The beneficial ownership structure, involving a parent holding company (FMR LLC) and its various investment adviser and trust company subsidiaries, is a standard practice for large financial institutions managing diverse client portfolios.

Related Party Transactions

• Abigail P. Johnson, a reporting person, is a Director, Chairman, and Chief Executive Officer of FMR LLC, the other reporting person.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners of FMR LLC's Series B voting common shares, representing 49% of the voting power, and form a controlling group with respect to FMR LLC.

Stakeholder Impact

• Shareholders: The continued significant ownership by a major institutional investor like FMR LLC may instill confidence among other shareholders, signaling a belief in Moderna's long-term value.
• Management: The presence of a large, stable institutional shareholder can influence corporate governance and strategic decisions, though this filing does not indicate any active intent to change or influence control.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership by a major institutional investor, FMR LLC, and its affiliates. While the 10.6% stake in Moderna Inc. is substantial and indicates continued institutional confidence, the filing itself does not provide new fundamental information about Moderna's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily confirms an existing significant position, suggesting a 'hold' stance for investors awaiting more substantive company-specific news.

Keywords

Moderna Inc, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, MRNA, Fidelity